STOCK TITAN

MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

MetaVia (MTVA) completed the last patient visit in the extended 24-week Phase 1 Part 3A study of DA-1726.

Treatment was extended from 16 to 24 weeks, adding eight weeks at 48 mg weekly. The company cited preliminary safety and tolerability observations as the reason. Previously reported Part 3B interim results showed a statistically significant 68.1% placebo-adjusted reduction in liver fat after 16 weeks and 13.5% placebo-adjusted weight loss at Day 109. All five treated participants with liver steatosis at baseline reached liver fat below 5% by Day 109, measured by MRI-PDFF, an MRI-based fat measurement.

MetaVia expects full Parts 3A and 3B data in the first quarter of 2027. It plans a 48-week, non-biopsy Phase 2 study in up to 150 patients with metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), targeting the second half of 2027.

Loading...
Loading translation...
9 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointLiver fat fell 68.1% versus placebo after 16 weeks in Part 3B interim results, a statistically significant reduction.
  • Moderate pointBody weight fell 13.5% versus placebo at Day 109 in the Part 3B interim analysis.
  • Moderate pointHbA1c, a blood-sugar measure, declined significantly in Part 3B interim results.
  • Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 2 study planned for up to 150 MetALD/ALD patients over 48 weeks, targeting the second half of 2027.
  • Minor pointLast patient visit completed in the extended 24-week Phase 1 Part 3A study of DA-1726.
4 minor points
  • Minor pointPreliminary safety and tolerability observations supported extending Part 3A treatment from 16 to 24 weeks at 48 mg weekly.
  • Minor pointAll five treated participants with baseline liver steatosis reached MRI-measured liver fat below 5% by Day 109.
  • Minor pointVisceral and subcutaneous fat declined, with relatively preserved lean mass in Part 3B interim results.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Full Parts 3A and 3B data are expected in the first quarter of 2027.

Negative

  • None.

Key Figures

Part 3A treatment period: 24 weeks (extended from 16 weeks) Extended dose: 48 mg weekly for an additional eight weeks Placebo-adjusted liver-fat reduction: 68.1% +5 more
Part 3A treatment period
24 weeks (extended from 16 weeks)
Phase 1 Part 3A
Extended dose
48 mg weekly for an additional eight weeks
Phase 1 Part 3A
Placebo-adjusted liver-fat reduction
68.1%
Phase 1 Part 3B interim results
Placebo-adjusted weight loss
13.5%
Phase 1 Part 3B interim results
Full Parts 3A and 3B data
Expected in the first quarter of 2027
DA-1726 Phase 1
Planned Phase 2 study duration
48 weeks
DA-1726 study in MetALD and ALD
Planned Phase 2 enrollment
Up to 150 patients
DA-1726 study in MetALD and ALD
Planned Phase 2 start
Targeted for the second half of 2027
DA-1726 study in MetALD and ALD

Previous Clinical trial Reports

2 past events · Latest: Nov 12
Same Type 2 events
  1. Nov 12

    Phase 1 clinical data

    24h Move
    -9.7%

    Statistically significant uric-acid reduction added to earlier Part 3B interim findings.

  2. Nov 05

    Phase 1 clinical data

    24h Move
    -18.7%

    Part 3B interim results reported liver-fat and weight reductions, alongside a possibly related serious vomiting event.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

dual-receptor agonist, mri-pdff, hba1c, subcutaneous
4 terms
dual-receptor agonist medical
"a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist"
A dual-receptor agonist is a drug or biologic that binds to and activates two different cell-surface receptors, causing both receptors’ signalling pathways to be turned on. It can be a single molecule engineered to interact with two targets or a co-formulation of two agonists, and its therapeutic effects and side effects come from the combined activation of those distinct receptors. The term denotes activation (agonism), not blocking or inhibiting, and the clinical effect depends on which receptors are targeted, their relative activation strength, and how those signalling pathways interact in the body.
mri-pdff medical
"as measured by MRI-PDFF"
MRI-PDFF (Magnetic Resonance Imaging-Proton Density Fat Fraction) is a medical imaging technique that measures the amount of fat within the liver or other tissues. For investors, it provides a precise way to assess health risks related to fat buildup, which can impact healthcare costs and the valuation of related companies. Its accuracy helps in monitoring treatment progress and predicting potential medical expenses, making it relevant for healthcare decision-making and investment considerations.
hba1c medical
"reductions in body weight, HbA1c and adipose tissue"
A1c (HbA1c) is a blood test that measures how much sugar has stuck to red blood cells over the past two to three months, giving a single number that reflects average blood glucose control—think of it as a running average score for blood sugar. Investors watch A1c because it’s a common clinical measure used to judge whether diabetes drugs, devices or care programs work, influence regulatory approvals, treatment guidelines and market demand.
subcutaneous medical
"designed for once weekly, subcutaneous administration"
Subcutaneous means situated or applied just beneath the skin. In finance, the term can describe processes or investments that are hidden or not immediately visible, much like something placed under the skin that isn't easily seen from the outside. Recognizing subcutaneous activities helps investors understand underlying factors that may influence markets or asset values over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks

Positive Part 3B Interim Data Presented at Precision Liver Symposium Demonstrated Statistically Significant 68.1% Placebo-Adjusted Reduction in Liver Fat

Full Data from Parts 3A and 3B Expected in First Quarter of 2027; Phase 2 Study in MetALD and ALD Planned for Second Half of 2027

CAMBRIDGE, Mass., Nov. 17, 2026 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced that the last patient has completed the final study visit for its Phase 1 clinical trial evaluating DA-1726, a novel GLP-1 (GLP1R)/glucagon (GCGR) dual-receptor agonist. MetaVia elected to extend the treatment period from 16 to 24 weeks, with patients receiving 48 mg of DA-1726 weekly for an additional eight weeks. In parallel, the company analyzed and previously released the data from part 3B, in which patients were titrated from 16 mg to 32 mg and ultimately to 64 mg of DA-1726 weekly during the 16-week regimen, accelerating towards Phase 2 readiness.

MetaVia Logo

"The encouraging preliminary safety and tolerability observations in Part 3A supported our decision to extend treatment for an additional eight weeks at the 48 mg dose, providing an opportunity to further assess the durability of treatment effects and longer-term safety of DA-1726." stated Hyung Heon Kim, President and Chief Executive Officer of MetaVia. "Simultaneously, we were finalizing the Part 3B interim data for presentation at the Precision Liver Symposium 2026 and advancing preparations for Phase 2 development. The recently reported Part 3B interim results demonstrated a statistically significant 68.1% placebo-adjusted reduction in liver fat, accompanied by 13.5% placebo-adjusted weight loss and improvements in glycemic control. These findings further strengthen our confidence in the potential of DA-1726 to address multiple aspects of liver-related cardiometabolic disease."

Mr. Kim continued, "We look forward to reporting the full data from Parts 3A and 3B in the first quarter of 2027, which we expect will provide additional insight into the safety, tolerability and metabolic effects of DA-1726. Building on these encouraging findings, we are preparing to initiate a 48-week, non-biopsy Phase 2 study in up to 150 patients with metabolic dysfunction and alcohol-associated liver disease (MetALD) and alcohol-associated liver disease (ALD), targeted to begin in the second half of 2027."

In the previously reported Phase 1 Part 3B interim analysis, DA-1726 demonstrated a statistically significant 68.1% placebo-adjusted reduction in liver fat, as measured by MRI-PDFF, following 16 weeks of treatment. All five DA-1726-treated participants with liver steatosis at baseline achieved MRI-PDFF below 5% by Day 109. These findings, together with significant reductions in body weight, HbA1c and adipose tissue, and preservation of lean mass, support the potential of DA-1726 as a differentiated treatment for liver-related cardiometabolic diseases.

About DA-1726
DA-1726 is a novel GLP1R/GCGR dual agonist being developed to address various cardiometabolic indications, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), which is designed for once weekly, subcutaneous administration. DA-1726 acts as a dual agonist of GLP-1 receptors (GLP1R) and glucagon receptors (GCGR), leading to weight loss through reduced appetite and increased energy expenditure. It is engineered with a 3:1 GLP1R:GCGR potency ratio intended to balance the complementary effects of GLP1R activation on appetite and glucose control with GCGR activation on energy expenditure and fat breakdown. DA-1726 has a well understood mechanism and preclinical tissue-distribution studies have shown that it concentrates most heavily in adipose tissue and in the liver. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated a 13.5% placebo-adjusted reduction in body weight and a 68.1% placebo-adjusted reduction in liver fat, along with reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass. MetaVia is planning a Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, targeted to begin in the second half of 2027.

About MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of various cardiometabolic conditions, with potential in both Metabolic and Alcohol-Associated Liver Disease (MetALD) and Alcohol-Associated Liver Disease (ALD), and is advancing vanoglipel (DA-1241) in combination with resmetirom for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist, engineered with a 3:1 GLP1R:GCGR potency ratio. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure. In a Phase 1 Part 3B interim analysis at Day 109, DA-1726 demonstrated placebo-adjusted reductions of 13.5% in body weight and 68.1% in liver fat, along with reductions in visceral and subcutaneous adipose tissue and relatively preserved lean mass. A Phase 2, 48-week, non-biopsy study of DA-1726 in MetALD and ALD, is targeted to begin in the second half of 2027. Vanoglipel is a potential first-in-class drug candidate targeting G-protein-coupled receptor 119 (GPR119). It acts directly in the liver on pathways involved in steatosis, inflammation and fibrosis, while GPR119 activation in the pancreas and gut also supports glucose and metabolic regulation. In a Phase 2a clinical study, vanoglipel demonstrated direct hepatic action in addition to its glucose lowering effects. MetaVia is advancing vanoglipel in combination with resmetirom as a once-daily oral combination therapy for MASH, with a Phase 2a proof-of-concept study targeted to begin in the first half of 2027.

For more information, please visit www.metaviatx.com.

Forward Looking Statements
Certain statements in this press release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believes", "expects", "anticipates", "may", "will", "should", "seeks", "approximately", "potential", "intends", "projects", "plans", "estimates" or the negative of these words or other comparable terminology (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including, without limitation, those risks associated with MetaVia's history of net losses, the sufficiency of its existing cash on hand to fund operations and raising additional capital; adverse global economic conditions; MetaVia's ability to execute on its commercial strategy; the timeline for regulatory submissions; the ability to obtain regulatory approval through the development steps of MetaVia's current and future product candidates; the ability to realize the benefits of the license agreement with Dong-A ST Co. Ltd., including the impact on future financial and operating results of MetaVia; the cooperation of MetaVia's contract manufacturers, clinical study partners and others involved in the development of MetaVia's current and future product candidates; potential negative interactions between MetaVia's product candidates and any other products with which they are combined for treatment; MetaVia's ability to obtain, maintain, protect and/or enforce sufficient intellectual property rights to execute its commercial strategy; MetaVia's ability to initiate and complete clinical trials on a timely basis; MetaVia's ability to recruit subjects for its clinical trials; whether MetaVia receives results from MetaVia's clinical trials that are consistent with the results of preclinical and previous clinical trials; impact of costs related to the license agreement, known and unknown, including costs of any litigation or regulatory actions relating to the license agreement; the effects of changes in applicable laws, regulations or Nasdaq listing rules; the effects of changes to MetaVia's stock price; and other risks and uncertainties described in MetaVia's filings with the Securities and Exchange Commission, including MetaVia's most recent Annual Report on Form 10-K. Forward-looking statements speak only as of the date when made. MetaVia does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts:

MetaVia
Marshall H. Woodworth
Chief Financial Officer
+1-857-299-1033
marshall.woodworth@metaviatx.com

Rx Communications Group
Michael Miller
+1-917-633-6086
mmiller@rxir.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/metavia-announces-completion-of-last-patient-visit-in-extended-24-week-phase-1-part-3a-study-of-da-1726-302941712.html

SOURCE MetaVia Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What milestone did MetaVia reach in the DA-1726 Phase 1 Part 3A study?

MetaVia completed the last patient visit in the extended 24-week Part 3A study. Treatment had been extended from 16 to 24 weeks, with an additional eight weeks at 48 mg weekly. Full Parts 3A and 3B data are expected in the first quarter of 2027.

What did MetaVia's DA-1726 Phase 1 Part 3B interim results show?

Part 3B interim results showed a statistically significant 68.1% placebo-adjusted reduction in liver fat following 16 weeks of treatment and a 13.5% placebo-adjusted reduction in body weight at Day 109. All five treated participants with liver steatosis at baseline reached MRI-measured liver fat below 5% by Day 109.

What doses were used in MetaVia's DA-1726 Phase 1 Part 3B study?

Patients in Part 3B were titrated from 16 mg to 32 mg and ultimately to 64 mg weekly during the 16-week regimen.

Keep reading